Canada Markets closed

Revive Therapeutics Ltd. (RVV.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.2500+0.0050 (+2.04%)
At close: 3:59PM EDT
Sign in to post a message.
  • L
    LONG+STRONG
    What are the chances of Bucillamine getting fast tracked by FDA if it shows good results with its first 210 patients? I’m thinking that due to its 30 year safety record this may be he case and a safe gamble.
  • j
    james
    Hey!! don’t forget that Revive Therapeutics first and foremost is an excellent psychedelics company , that’s why I originally invested in them, the psychedelics / psilocybin space is fast becoming a huge market and 5 states have already legalized the use of psilocybin with Oregon set to legalize by November 2020,Rivive was and still is my number one pick for a psychedelic company that’s making a difference and who is on top of their game , also EHAVE Inc if your looking for a huge opportunity ,a great little company as well and has been around longer than most in the psychedelic space ,true pioneers, Revive Therapeutics is a great company , Bucillamine I think will be a huge win for them and investors who can stick it out will win as well GLTA
  • S
    Snowflake Warrior
    Over 300000 traded in the last 20 mins on the American exchange, lots of buying. Something is up and breakout is happening.
  • M
    Mr.Normall (Troll Hunter)
    When you are a company with many smart people in the forefront and behind the scenes you are generally undervalued and kicked around while the flashy companies get attention. As the past has shown us the brains always bring the money in the end. See you in November EOM
  • R
    Rudolph
    So what does this communicate? Confirmation of a plan moving forward. The company is now comfortable with the drug delivery system and now they are ready to proceed. Next step? Get a supply of the drug.
    Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
  • J
    James
    This will be a $20 stock this coming Spring.
  • l
    l
    Santen.. market cap.. 833 billion.. these are the people we got the rights for bucillamine from cov19 from.. again weak hands selling d/t the news not Being phase 3 r/t. Not worried a bit. Santen market cap helps me sleep like a baby
  • L
    Lars
    Everybody here stressing out and selling off does realize that "Bucillamine in COVID-19" primary completion is scheduled for Feb 2021, with final data planned for May 2021? Patience.
  • D
    Danielek
    3 more days till earnings call..there shoild be a little jump in yh4 next couple of days and a big jump during a comany released PR...lets hope so anyways...good luck everyone..
  • M
    Matt
    Good volume today. Atleast that's a good sign.
  • l
    l
    Just look at santen pharmas market cap and stop worrying, if prelim results are good, funding won’t be a issue because big pharma japan is all over it
  • l
    l
    Santen did a study, see their stock price and look at the study summary Hahah :) https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2249.1999.00749.x
  • A
    Andy
    Please stop with the fluffy pr articles. They do nothing for the sp.
  • T
    Trader
    APP.CN the best stock for traders
  • j
    jim
    Very low volume. I like that. Hmmm. It's time to start buying again. How much can I lose at these prices?
  • D
    David
    https://www.instagram.com/p/CGa1PqDH-s1/?igshid=1h4ol7dhwaz9r

    the shroom boom is coming. news is spreading. we have the covid play and mushrooms play. both of which are huge center points right now
  • l
    l
    Glutathione is reduced in people from a ratio of 1:100 (normal) to 1:10 or less in people with covid. Glutathione is the key to interfering with viral replication at ace II due to the glutathione imbalance that makes the ace II receptors more susceptible to viral replication. Repleting and arguably Increasing free glutathione levels will convert oxidized glutathione which is the byproduct of damage from ros, decreasing the activity of ros by restoring the body’s number one antioxidant (glutathione) should provide the body with a restored first line defence against fighting the damage from the virus, in turn the body’s chemical signals will interrupt the body’s activation of IL-6 and Il-8 factors which lead to cytokine storm . Revive Will equal = first line therapeutic. It will take time, but time we have, glta
  • l
    l
    Hoping we get a meaningful update on the bucillamine trial this week, that’s what this sp is riding on, come on micheal give us a solid update
  • L
    Lillian
    Are you Ready to ROCK the Stock Market?!? | www.StockRockandRoll.com
  • D
    Danielek
    those that are complaining about RVV i bet are the once that boughy High after PR was released...mistake number 1 is to never buy after PR is released, but rather yo buy before any news gets released and after days of consolidation after PR and huge sell off...i learned that lessen already with other stocks...buy before the news, and sell after....much better strategy...good luck all